March 1 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd:
* BIOHAVEN ANNOUNCES POSITIVE RESULTS FROM BIOEQUIVALENCE STUDY WITH SUBLINGUAL RIMEGEPANT ZYDIS® ORALLY DISSOLVING TABLET
* BIOHAVEN IS PLANNING TO INITIATE A PHASE 3 TRIAL WITH RIMEGEPANT ZYDIS(®) ODT IN Q1 OF 2018 Source text for Eikon: Further company coverage: